Common Genetic Variation Within IGFI, IGFII, IGFBP-1, and IGFBP-3 and Endometrial Cancer Risk

Overview

Journal Gynecol Oncol

Date 2010 Nov 17

PMID 21078522

Citations 14

Authors

Monica McGrath

I-Min Lee

Julie Buring

Immaculata De Vivo

Affiliations

Soon will be listed here.

Abstract

Objective: The insulin-like growth factor (IGF) pathway plays a critical role in the growth and development of the uterus and is believed to function as a mediator of steroid hormone actions in the endometrium. The local expression of genes encoding IGFs and IGF-binding proteins (IGFBPs) is important in determining IGF bioactivity in the uterus. Genetic variation in key genes within the IGF pathway may influence the rate of cellular proliferation and differentiation in the uterus and ultimately affect the risk of endometrial cancer. Our hypothesis is that variant alleles in key genes involved in the IGF pathway will influence the development of endometrial cancer.

Methods: We conducted a case-control study nested within the Nurses' Health Study (NHS) and the Women's Health Study (WHS) to investigate the association between forty-four polymorphisms within IGFI, IGFII, IGFBP-1, and IGFBP-3 with endometrial cancer risk using 692 invasive endometrial cancer cases and 1723 matched controls. We used conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to assess the risk of endometrial cancer.

Results: We observed an inverse association with IGFII rs3741211 and endometrial cancer risk (OR=0.79 (95% CI: 0.63, 0.99)) and IGFII rs1004446 and endometrial cancer risk (OR=0.80 (95% CI: 0.68, 0.94)). We also observed an inverse association with IGFBP-3 rs2453839 and endometrial cancer risk (OR=0.81 (95%CI: 0.67, 0.98). However, we did not observe any statistically significant associations with the polymorphisms in IGFI and IGFBP1 and endometrial cancer risk.

Conclusions: Genetic variation with IGFII and IGFBP-3 may influence endometrial cancer risk in Caucasians. Polymorphisms in IGFI and IGFBP-1 were not associated with endometrial cancer risk, but further research is needed.

Citing Articles

Insulin-like Growth Factor 1 (IGF1) and Its Isoforms: Insights into the Mechanisms of Endometrial Cancer.

Hafizz A, Mohd Mokthar N, Md Zin R, Mongan N, Mamat Yusof M, Kampan N Cancers (Basel). 2025; 17(1.

PMID: 39796756 PMC: 11720045. DOI: 10.3390/cancers17010129.

Association between IGFBP1 expression and cancer risk: A systematic review and meta-analysis.

Zhang B, Hong C, Lin Y, Luo Y, Ding T, Xu Y Heliyon. 2023; 9(6):e16470.

PMID: 37251476 PMC: 10220379. DOI: 10.1016/j.heliyon.2023.e16470.

Role of in the Study of Development and Evolution of Prostate Cancer.

Porras-Quesada P, Gonzalez-Cabezuelo J, Sanchez-Conde V, Puche-Sanz I, Arenas-Rodriguez V, Garcia-Lopez C Front Genet. 2022; 12:740641.

PMID: 35095996 PMC: 8790605. DOI: 10.3389/fgene.2021.740641.

IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications.

Lin Y, Weng X, Huang B, Guo H, Xu Y, Peng Y Am J Transl Res. 2021; 13(3):813-832.

PMID: 33841624 PMC: 8014352.

Association of polymorphisms of preptin, irisin and adropin genes with susceptibility to coronary artery disease and hypertension.

Wang H, Wang X, Cao Y, Han W, Guo Y, Yang G Medicine (Baltimore). 2020; 99(10):e19365.

PMID: 32150081 PMC: 7478509. DOI: 10.1097/MD.0000000000019365.

References

Cheng I, Penney K, Stram D, Le Marchand L, Giorgi E, Haiman C . Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1993-7. DOI: 10.1158/1055-9965.EPI-06-0361. View

Rutanen E, Pekonen F, Makinen T . Soluble 34K binding protein inhibits the binding of insulin-like growth factor I to its cell receptors in human secretory phase endometrium: evidence for autocrine/paracrine regulation of growth factor action. J Clin Endocrinol Metab. 1988; 66(1):173-80. DOI: 10.1210/jcem-66-1-173. View

Rutanen E . Insulin-like growth factors in endometrial function. Gynecol Endocrinol. 1999; 12(6):399-406. DOI: 10.3109/09513599809012842. View

Fletcher O, Gibson L, Johnson N, Altmann D, Holly J, Ashworth A . Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(1):2-19. View

Frost R, Mazella J, Tseng L . Insulin-like growth factor binding protein-1 inhibits the mitogenic effect of insulin-like growth factors and progestins in human endometrial stromal cells. Biol Reprod. 1993; 49(1):104-11. DOI: 10.1095/biolreprod49.1.104. View

Rutanen E, Nyman T, Lehtovirta P, Ammala M, Pekonen F . Suppressed expression of insulin-like growth factor binding protein-1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors. Int J Cancer. 1994; 59(3):307-12. DOI: 10.1002/ijc.2910590303. View

McGrath M, Lee I, Buring J, Hunter D, De Vivo I . Novel breast cancer risk alleles and endometrial cancer risk. Int J Cancer. 2008; 123(12):2961-4. PMC: 2605169. DOI: 10.1002/ijc.23862. View

Juul A, Scheike T, Nielsen C, Krabbe S, Muller J, Skakkebaek N . Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an.... J Clin Endocrinol Metab. 1995; 80(10):3059-67. DOI: 10.1210/jcem.80.10.7559897. View

Patel A, Cheng I, Canzian F, Le Marchand L, Thun M, Berg C . IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008; 3(7):e2578. PMC: 2440354. DOI: 10.1371/journal.pone.0002578. View

10.

Verhaeghe J, Loos R, Vlietinck R, Herck E, Van Bree R, Schutter A . C-peptide, insulin-like growth factors I and II, and insulin-like growth factor binding protein-1 in cord serum of twins: genetic versus environmental regulation. Am J Obstet Gynecol. 1996; 175(5):1180-8. DOI: 10.1016/s0002-9378(96)70025-x. View

11.

Canzian F, McKay J, Cleveland R, Dossus L, Biessy C, Rinaldi S . Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer. 2006; 94(2):299-307. PMC: 2361124. DOI: 10.1038/sj.bjc.6602936. View

12.

Terry K, Tworoger S, Gates M, Cramer D, Hankinson S . Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk. Carcinogenesis. 2009; 30(12):2042-6. PMC: 2792318. DOI: 10.1093/carcin/bgp257. View

13.

Zendehdel K, Nyren O, Ostenson C, Adami H, Ekbom A, Ye W . Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003; 95(23):1797-800. DOI: 10.1093/jnci/djg105. View

14.

Kao P, Matheny Jr A, LANG C . Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab. 1994; 78(2):310-2. DOI: 10.1210/jcem.78.2.8106617. View

15.

Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y . Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet. 2009; 17(12):1668-75. PMC: 2987015. DOI: 10.1038/ejhg.2009.86. View

16.

Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J . Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996; 98(11):2612-5. PMC: 507720. DOI: 10.1172/JCI119081. View

17.

Oh J, Wu W, Tortolero-Luna G, Broaddus R, Gershenson D, Burke T . Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004; 13(5):748-52. View

18.

Ketelslegers J, Maiter D, Maes M, Underwood L, Thissen J . Nutritional regulation of insulin-like growth factor-I. Metabolism. 1995; 44(10 Suppl 4):50-7. DOI: 10.1016/0026-0495(95)90221-x. View

19.

Pollak M . Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000; 36(10):1224-8. DOI: 10.1016/s0959-8049(00)00102-7. View

20.

Cheng I, Stram D, Penney K, Pike M, Le Marchand L, Kolonel L . Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst. 2006; 98(2):123-34. DOI: 10.1093/jnci/djj013. View